PURPOSE: This is a single-center uncontrolled retrospective study to evaluate the efficacy and safety of the biosimilar @entity1307 zeta after approval in @entity417 ( @entity417 ). METHODS: @entity1 screened were >18  years old suffering from solid @entity5 and @entity417 with @entity5332 <= 10 or <11  g/dl if symptomatic @entity417 . @entity1 had measurable disease by TNM and Eastern Cooperative Oncology Group (ECOG). @entity1 were treated for at least 12  weeks and the primary endpoint was to determine the incidence of blood transfusions, and secondarily, the overall safety and efficacy defined as >= 1  g/dl rise in Hb concentration or >= 40,000  cells/ l rise in reticulocyte count. Quality of life was assessed with ECOG performance status (PS) and functional assessment of @entity5 (FACT-An) score. RESULTS: 1287 @entity1 with median Hb 9.3  g/dl (range 8.3-10.6) were enrolled and included in the evaluation. Median age was 63  years (range 33-78). 74% of @entity1 were stage III/IV. @entity1 received @entity1307 zeta subcutaneously at fixed 40,000-IU once weekly. Blood transfusions were given in 178 @entity1 (13.8%; 95% CI 11.9-15.6%). Appropriate response was observed in 79% @entity1 by week 4, 87% by week 8, and 91% by week 12. A mean Hb increase of 2.5  g/dl was observed by week 12 which correlated with an improvement in PS and Fact-An score. @entity715 events occurred in 5.2% (95% CI 3.4-7.1%) of @entity1 . CONCLUSIONS: @entity1307 zeta is effective in palliation and treatment of @entity417 in @entity1 with @entity5 . Overall, it is well tolerated and safe even in @entity1 with @entity66 .

A retrospective open-label uncontrolled study of @entity1307 zeta on the treatment of XXXX in @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5332 :: ('D008628', 'Chemical') :: ['Hg'] @entity417 :: ('MESH:D000740', 'Disease') :: ['chemotherapy-induced anemia', 'CIA', 'anemia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['increased disease burden'] @entity5 :: ('MESH:D009369', 'Disease') :: ['solid tumors', 'cancer therapy-anemia', 'malignancies'] @entity1307 :: ('2056', 'Gene') :: ['epoetin', 'Epoetin'] @entity715 :: ('MESH:D013927', 'Disease') :: ['Thrombotic']
@entity417 :: (MESH:D000740,Disease) :: ['chemotherapy-induced anemia']
